Myelodysplastic syndromes and acute leukemia developing after imatinib mesylate therapy for chronic myeloid leukemia.

During therapy with imatinib, some patients with chronic myeloid leukemia (CML) develop chromosomal abnormalities in Philadelphia chromosome (Ph)-negative cells. These abnormalities are frequently transient and their clinical consequence is unclear. Although some reports have suggested that the abnormalities might be associated with secondary myelodysplastic syndrome (MDS), the diagnosis has not always been established using standard criteria. We report 3 cases of patients treated with imatinib for CML who were subsequently found to have chromosomal abnormalities in Ph-negative cells. One of them developed acute myelogenous leukemia (AML) and the other 2 developed high-risk MDS that rapidly transformed to AML. These cases were identified in a total study group of 1701 patients. Although these occurrences are rare, the findings highlight the need for close monitoring of patients with CML treated with imatinib.

[1]  W. Hiddemann,et al.  Clonal aberrations in Philadelphia chromosome negative hematopoiesis in patients with chronic myeloid leukemia treated with imatinib or interferon alpha , 2005, Leukemia.

[2]  G. Kennedy,et al.  Clinical significance of development of Philadelphia-chromosome negative clones in patients with chronic myeloid leukemia treated with imatinib mesylate. , 2005, Haematologica.

[3]  L. Trakhtenbrot,et al.  Reciprocal Relationship Between a Ph‐Negative Clone With Trisomy 8 Associated With Severe Myelodysplasia and a Ph‐Positive Clone Following Imatinib Treatment in a Patient With Accelerated‐Phase Chronic Myelogenous Leukemia (CML) , 2004, American journal of hematology.

[4]  G. Flandrin,et al.  Report of 34 patients with clonal chromosomal abnormalities in Philadelphia-negative cells during imatinib treatment of Philadelphia-positive chronic myeloid leukemia , 2004, Leukemia.

[5]  Jorge Cortes,et al.  Clonal evolution in chronic myelogenous leukemia. , 2004, Hematology/oncology clinics of North America.

[6]  C. Berthou,et al.  Clonal chromosomal abnormalities in the Philadelphia chromosome negative cells of chronic myeloid leukemia patients treated with imatinib , 2004, Leukemia.

[7]  P. Simi,et al.  Adjunctive chromosomal abnormalities in Philadelphia‐negative cells of CML patients treated with Imatinib , 2004, European journal of clinical investigation.

[8]  M. Mancini,et al.  Clonal evolution in Philadelphia chromosome negative cells following successful treatment with Imatinib of a CML patient: clinical and biological features of a myelodysplastic syndrome , 2004, Leukemia.

[9]  D. Swirsky,et al.  Development and progression of a Philadelphia-chromosome-negative acute myelocytic leukemia clone in a patient with Philadelphia-chromosome-positive chronic myelocytic leukemia. , 2004, Cancer genetics and cytogenetics.

[10]  Miae Lee,et al.  Acute lymphoblastic leukemia without the Philadelphia chromosome occurring in chronic myelogenous leukemia with the Philadelphia chromosome , 2003, American journal of hematology.

[11]  H. Kantarjian,et al.  Chromosomal abnormalities in Philadelphia chromosome‐negative metaphases appearing during imatinib mesylate therapy in patients with Philadelphia chromosome‐positive chronic myelogenous leukemia in chronic phase , 2003, Cancer.

[12]  F. Baron,et al.  Clonal chromosome aberrations in Philadelphia-negative cells from chronic myelocytic leukemia patients treated with imatinib mesylate: report of two cases. , 2003, Cancer genetics and cytogenetics.

[13]  A. Hagemeijer,et al.  Philadelphia-negative acute lymphoblastic leukemia developing in a CML patient in imatinib mesylate-induced complete cytogenetic remission , 2003, Leukemia.

[14]  D. Blaise,et al.  Myelodysplastic features developing in Philadephia-negative cells during imatinib mesylate therapy for CML: report of a new case , 2003, Leukemia.

[15]  T. Holyoake,et al.  Fatal myelodysplastic syndrome developing during therapy with imatinib mesylate and characterised by the emergence of complex Philadelphia negative clones , 2003, Leukemia.

[16]  R. Braziel,et al.  Demonstration of Philadelphia chromosome negative abnormal clones in patients with chronic myelogenous leukemia during major cytogenetic responses induced by imatinib mesylate , 2003, Leukemia.

[17]  K. Krohn,et al.  Emergence of clonal cytogenetic abnormalities in Ph- cells in some CML patients in cytogenetic remission to imatinib but restoration of polyclonal hematopoiesis in the majority. , 2003, Blood.

[18]  A. Hagemeijer,et al.  Sustained, clonal karyotype abnormalities in the Philadelphia chromosome negative cells of CML patients successfully treated with Imatinib , 2003, Leukemia.

[19]  R. Braziel,et al.  Hematopathologic and cytogenetic findings in imatinib mesylate-treated chronic myelogenous leukemia patients: 14 months' experience. , 2002, Blood.

[20]  S. Bose,et al.  Lymphoid blast crisis during complete cytogenetic remission following interferon-alpha and hydroxyurea therapy. , 1997, Acta haematologica.

[21]  M. Talpaz,et al.  Emergence of new clonal abnormalities following interferon-alpha induced complete cytogenetic response in patients with chronic myeloid leukemia: report of three cases , 1997, Leukemia.

[22]  M. Nasu,et al.  Acute myeloblasts leukaemia without Philadelphia chromosome developing after interferon therapy for chronic myelocytic leukaemia with Philadelphia chromosome , 1995, British Journal of Haematology.

[23]  G. Janossy,et al.  The Ph1 Chromosome in Childhood Leukaemia , 1979, British journal of haematology.

[24]  A. Hagemeijer,et al.  Chronic myeloid leukemia with permanent disappearance of the Ph1 chromosome and development of new clonal subpopulations. , 1979, Blood.